IQVIA Holdings Inc. (NYSE:IQV – Get Free Report) was the recipient of a large growth in short interest in August. As of August 15th, there was short interest totalling 2,400,000 shares, a growth of 7.6% from the July 31st total of 2,230,000 shares. Approximately 1.3% of the shares of the stock are short sold. Based on an average daily volume of 990,200 shares, the short-interest ratio is currently 2.4 days.
IQVIA Price Performance
NYSE:IQV opened at $222.63 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 2.16. The firm has a fifty day simple moving average of $220.34 and a 200 day simple moving average of $208.18. IQVIA has a 1-year low of $165.75 and a 1-year high of $241.86. The stock has a market capitalization of $40.77 billion, a PE ratio of 38.32, a P/E/G ratio of 2.25 and a beta of 1.37.
IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings data on Tuesday, August 1st. The medical research company reported $2.22 EPS for the quarter, topping analysts’ consensus estimates of $2.09 by $0.13. IQVIA had a net margin of 7.47% and a return on equity of 30.14%. The firm had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.70 billion. On average, research analysts expect that IQVIA will post 9.21 EPS for the current fiscal year.
Analyst Ratings Changes
Insider Activity at IQVIA
In other IQVIA news, insider Kevin C. Knightly sold 5,820 shares of IQVIA stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $201.89, for a total value of $1,174,999.80. Following the sale, the insider now owns 1,973 shares of the company’s stock, valued at approximately $398,328.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of IQV. Bank Julius Baer & Co. Ltd Zurich increased its stake in shares of IQVIA by 59,295.3% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 57,650,851 shares of the medical research company’s stock valued at $12,958,182,000 after buying an additional 57,553,788 shares during the period. State Street Corp raised its stake in shares of IQVIA by 2.5% during the 2nd quarter. State Street Corp now owns 8,451,571 shares of the medical research company’s stock worth $1,899,660,000 after purchasing an additional 207,148 shares during the period. Alliancebernstein L.P. raised its stake in IQVIA by 19.1% in the 2nd quarter. Alliancebernstein L.P. now owns 5,942,761 shares of the medical research company’s stock valued at $1,335,754,000 after acquiring an additional 952,850 shares during the period. FMR LLC grew its holdings in IQVIA by 24.7% during the 1st quarter. FMR LLC now owns 5,620,968 shares of the medical research company’s stock valued at $1,117,954,000 after buying an additional 1,111,803 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in IQVIA by 2.7% in the 2nd quarter. Geode Capital Management LLC now owns 3,907,023 shares of the medical research company’s stock worth $875,861,000 after buying an additional 102,862 shares during the last quarter. Institutional investors and hedge funds own 86.82% of the company’s stock.
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Five stocks we like better than IQVIA
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 Takeaways from the August Inflation Report
- 5 Top Rated Dividend Stocks to Consider
- On Fire: 5 Best Artificial Intelligence Penny Stocks
- 3 Tickers Leading a Meme Stock Revival
- 6 Cybersecurity Stocks: Which is the Best to Buy?
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.